相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Progranulin and granulin-like protein as novel VEGF-independent angiogenic factors derived from human mesothelioma cells
R. Eguchi et al.
ONCOGENE (2017)
A humanized anti-CD26 monoclonal antibody inhibits cell growth of malignant mesothelioma via retarded G2/M cell cycle transition
Mutsumi Hayashi et al.
CANCER CELL INTERNATIONAL (2016)
Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial
Gerard Zalcman et al.
LANCET (2016)
DPPIV/CD26: a tumor suppressor or a marker of malignancy?
Aline Beckenkamp et al.
TUMOR BIOLOGY (2016)
Incidental Receipt of Cardiac Medications and Survival Outcomes Among Patients With Stage III Non-Small-Cell Lung Cancer After Definitive Radiotherapy
Hongmei Wang et al.
CLINICAL LUNG CANCER (2015)
Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
Rosa Barreira da Silva et al.
NATURE IMMUNOLOGY (2015)
Therapeutic Effects of Repurposed Therapies in Non-Small Cell Lung Cancer: What Is Old Is New Again
Ashish Saxena et al.
ONCOLOGIST (2015)
Newly synthesized anticancer drug HUHS1015 is effective on malignant pleural mesothelioma
Yoshiko Kaku et al.
CANCER SCIENCE (2014)
Phase II Clinical Trial of Amatuximab, a Chimeric Antimesothelin Antibody with Pemetrexed and Cisplatin in Advanced Unresectable Pleural Mesothelioma
Raffit Hassan et al.
CLINICAL CANCER RESEARCH (2014)
Naftopidil Is Useful for the Treatment of Malignant Pleural Mesothelioma
Koji Mikami et al.
PHARMACOLOGY (2014)
Improved survival outcomes with the incidental use of beta-blockers among patients with non-small-cell lung cancer treated with definitive radiation therapy
H. M. Wang et al.
ANNALS OF ONCOLOGY (2013)
Oral Naftopidil Suppresses Human Renal-Cell Carcinoma by Inducing G1 Cell-Cycle Arrest in Tumor and Vascular Endothelial Cells
Yoichi Iwamoto et al.
CANCER PREVENTION RESEARCH (2013)
Reduction of prostate cancer incidence by naftopidil, an α1-adrenoceptor antagonist and transforming growth factor-β signaling inhibitor
Daisuke Yamada et al.
INTERNATIONAL JOURNAL OF UROLOGY (2013)
Nuclear Localization of CD26 Induced by a Humanized Monoclonal Antibody Inhibits Tumor Cell Growth by Modulating of POLR2A Transcription
Kohji Yamada et al.
PLOS ONE (2013)
1-[2-(2-Methoxyphenylamino)ethylamino]-3-(naphthalene-1-yloxy)propan-2-ol as a Potential Anticancer Drug
Takeshi Kanno et al.
PHARMACOLOGY (2013)
CD26 Overexpression Is Associated with Prolonged Survival and Enhanced Chemosensitivity in Malignant Pleural Mesothelioma
Keisuke Aoe et al.
CLINICAL CANCER RESEARCH (2012)
Inhibition of dipeptidyl peptidase 4 regulates microvascular endothelial growth induced by inflammatory cytokines
Wataru Takasawa et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2010)
Mesothelin targeted cancer immunotherapy
Raffit Hassan et al.
EUROPEAN JOURNAL OF CANCER (2008)
Humanized anti-CD26 monoclonal antibody as a treatment for malignant mesothelioma tumors
Teruo Inamoto et al.
CLINICAL CANCER RESEARCH (2007)
Dipeptidyl peptidase inhibits malignant phenotype of prostate cancer cells by blocking basic fibroblast growth factor signaling pathway
UV Wesley et al.
CANCER RESEARCH (2005)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma
NJ Vogelzang et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog
HB Rasmussen et al.
NATURE STRUCTURAL BIOLOGY (2003)
分享论文
